Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06251492
Status:
RECRUITING
Last Update Posted:
2024-02-20
First Post:
2024-01-12
Brief Title:
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease RAPID
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease RAPIDa Prospective Single-arm Phase II Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the efficacy of 2 cycles of combinatory adebrelimab and stereotactic radiotherapy followed by monotherapy adebrelimab in patients with metastatic castration-resistant prostate cancer Dr Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None